Compile Data Set for Download or QSAR
Report error Found 104 Enz. Inhib. hit(s) with all data for entry = 12230
TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50406180(CHEMBL5276780 | US20240190892, Example 23)
Affinity DataIC50: 0.5nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50406177(CHEMBL5285047 | US20240190892, Example 15)
Affinity DataIC50: 0.600nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50406172(CHEMBL5290426 | US20240190892, Example 4)
Affinity DataIC50: 1.20nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50406178(CHEMBL5267934 | US20240190892, Example 20)
Affinity DataIC50: 1.30nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50406174(CHEMBL5274983 | US20240190892, Example 14)
Affinity DataIC50: 1.60nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50406322(CHEMBL5267385 | US20240190892, Example 43)
Affinity DataIC50: 1.70nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689070(US20240190892, Example 28 | (S)-6-(6-Chloro-5-fluo...)
Affinity DataIC50: 1.90nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689063(US20240190892, Example 21 | (S)-6-(6-Chloro-5-fluo...)
Affinity DataIC50: 2.30nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50406173(CHEMBL5270511 | US20240190892, Example 10)
Affinity DataIC50: 2.5nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689047(US20240190892, Example 5 | (S)-6-(6-Chloro-5-fluor...)
Affinity DataIC50: 3nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689068(US20240190892, Example 26 | (S)-5-(6-Chloro-5-fluo...)
Affinity DataIC50: 3.10nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689053(US20240190892, Example 11 | (S)-6-(6-Chloro-5-fluo...)
Affinity DataIC50: 3.90nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689048(US20240190892, Example 6 | (S)-6-(6-Chloro-5-fluor...)
Affinity DataIC50: 4nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689064(US20240190892, Example 22 | (S)-2-(6-Chloro-5-fluo...)
Affinity DataIC50: 4.70nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689071(US20240190892, Example 29 | (S)-6-(6-Chloro-5-fluo...)
Affinity DataIC50: 5nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689076(US20240190892, Example 34 | (S)-6-(6-Chloro-5-fluo...)
Affinity DataIC50: 5.40nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689090(US20240190892, Example 48 | (S)-6-(6-Chloro-5-fluo...)
Affinity DataIC50: 5.90nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689044(US20240190892, Example 2)
Affinity DataIC50: 6.80nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689051(US20240190892, Example 9 | (S)-6-(6-Chloro-5-fluor...)
Affinity DataIC50: 7.5nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689073(US20240190892, Example 31 | (S)-6-(6-Chloro-5-fluo...)
Affinity DataIC50: 8.60nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689091(US20240190892, Example 49 | (S)-6-(6-Chloro-5-fluo...)
Affinity DataIC50: 8.90nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689045(US20240190892, Example 3 | (S)-5-(6-Chloro-5-fluor...)
Affinity DataIC50: 9.5nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689084(US20240190892, Example 42 | (S)-6-(6-Chloro-5-fluo...)
Affinity DataIC50: 11.8nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689060(US20240190892, Example 18 | (S)-6-(6-Chloro-5-fluo...)
Affinity DataIC50: 12.8nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689066(US20240190892, Example 24 | (S)-2-(6-Chloro-5-fluo...)
Affinity DataIC50: 13.6nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689089(US20240190892, Example 47 | (S)-6-(6-chloro-5-fluo...)
Affinity DataIC50: 13.8nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689069(US20240190892, Example 27 | (S)-6-(6-Chloro-5-fluo...)
Affinity DataIC50: 14.3nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689087(US20240190892, Example 45 | N-(4-((sec- Butylamino...)
Affinity DataIC50: 15.8nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689059(US20240190892, Example 17 | (S)-6-(6-Chloro-5-fluo...)
Affinity DataIC50: 16.3nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689067(US20240190892, Example 25 | (S)-4-(6-Chloro-5-fluo...)
Affinity DataIC50: 16.5nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689082(US20240190892, Example 40 | N-((6-(3-Azabicyclo[3....)
Affinity DataIC50: 18.6nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689074(US20240190892, Example 32 | (S)-N-((1-Aminoisoquin...)
Affinity DataIC50: 19nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689094(US20240190892, Example 52)
Affinity DataIC50: 19nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50406171(CHEMBL5283110 | US20240190892, Example 1)
Affinity DataIC50: 19.3nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689072(US20240190892, Example 30 | (S)-6-(6-Chloro-5-fluo...)
Affinity DataIC50: 20.9nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689075(US20240190892, Example 33 | (S)-6-(6-Chloro-5-fluo...)
Affinity DataIC50: 25.4nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689061(US20240190892, Example 19 | (S)-6-(6-Chloro-5-fluo...)
Affinity DataIC50: 25.6nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689081(US20240190892, Example 39 | (S)-6-(6-Chloro-5-fluo...)
Affinity DataIC50: 25.8nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50406323(CHEMBL5273808 | US20240190892, Example 50)
Affinity DataIC50: 26.6nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689077(US20240190892, Example 35 | (S)-6-(6-chloro-5-fluo...)
Affinity DataIC50: 28.4nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689050(US20240190892, Example 8 | (S)-6-(6-Chloro-5-fluor...)
Affinity DataIC50: 30.4nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689049(US20240190892, Example 7 | (S)-6-(6-Chloro-5-fluor...)
Affinity DataIC50: 33.5nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689083(US20240190892, Example 41 | (S)-6-(6-Chloro-5-fluo...)
Affinity DataIC50: 35.4nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689080(US20240190892, Example 38 | (S)-6-(6-Chloro-5-fluo...)
Affinity DataIC50: 35.8nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689088(US20240190892, Example 46 | (S)-6-(6-Chloro-5-fluo...)
Affinity DataIC50: 38nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689054(US20240190892, Example 13 | (S)-6-(6-Chloro-5-fluo...)
Affinity DataIC50: 39.6nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689078(US20240190892, Example 36 | (S)-6-(6-Chloro-5-fluo...)
Affinity DataIC50: 43.7nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50406182(CHEMBL5268598 | US20240190892, Example 37)
Affinity DataIC50: 44.4nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689093(US20240190892, Example 51)
Affinity DataIC50: 45.9nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM689058(US20240190892, Example 16 | (S)-2-(6-Chloro-5-fluo...)
Affinity DataIC50: 50nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of plasma kallikrein can be determined using a relevant purified serine prot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 104 total ) | Next | Last >>
Jump to: